HRTX Dec 2024 2.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:39AM EDT. Market open.
| Previous close | 1.5700 |
| Open | 1.6500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.5700 - 1.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 35 |
PR NewswireHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN").
ZacksMerus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
ZacksIs CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
Here is how CareCloud, Inc. (CCLD) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
© 2024 Yahoo. All rights reserved.